Clinical Trial

Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

Study acronym: NIVONASO-21
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy . Patients disqualified from radical therapy . The total number of patients was estimated for 32.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-05-03; most recent amendment 2025-04-21.
Status change: Not Yet Recruiting → Recruiting 2025-04-21
Trial Details
NCT Number NCT04875611
Lead Sponsor Maria Sklodowska-Curie National Research Institute of Oncology
Collaborators: KCRI
Conditions Nasopharyngeal Cancer
Enrollment 32 participants
Start Date 2021-08-26
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-24